
Thursday,
May 5, 2022
17:30 CET

The NASDAQ IPO Path for Italian Life Science Companies: Genenta Science's Case Study

[Register to the
webinar](#)



Speakers:

- **Andrea Messuti (LCA Studio Legale)**
- **Ettore Santucci (Goodwin)**
- **Pierluigi Paracchi (Genenta)**
- **Aparna Beeram (Roth Capital Partners)**
- **Federica Draghi (Genextra)**
- **Leonardo Vingiani (Assobiotec-Federchimica)**

17:30	Leonardo Vingiani opens the webinar with welcoming remarks
17:35	Ettore Santucci and Andrea Messuti introduce the panelists and the agenda
17:40	Pierluigi Paracchi describes how Genenta Science prepared for a successful NASDAQ IPO: from early stage backing to advance the science in the lab, to VC rounds to fund R&D, pre-clinical and clinical studies, to the organizational growth and infrastructure build necessary to approach the listed market, culminating with the selection of a lead underwriter.
17:55	Aparna Beeram illustrates key attributes of an early stage life sciences company to be suitable for a NASDAQ IPO and the critical features that public market investors look for in assessing the issuer's potential as a successful listed company.
18:10	Federica Draghi illustrates the Italian ecosystem for hatching and supporting promising life sciences companies in their early stage, the private and public capital sources available for pre-IPO growth, and opportunities/challenges for companies that wish to get ready for the listed market.
18:25	Leonardo Vingiani concludes with an institutional message to its members and opens the Q&A segment
18:30	Q&A
18:45	Meeting ends